Benzinga's Microcap Movers for Wednesday September 19, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Geokinetics (NYSE: GOK), the Houston, TX provider of seismic data services, rose 31.98% Wednesday on 13 times average volume.
The company responded to unusual trading activity on Wednesday: "In view of the unusual market activity in the shares of Geokinetics, the NYSE staff has contacted the company in accordance with its usual practice and requested that the company issue a press release regarding Wednesday`s trading activity of its common stock. The company, in accordance with its usual practice, does not comment on unusual market activity or rumors".
Geokinetics closed at $0.62 on Wednesday.
Shares of Prana Biotechnology (NASDAQ: PRAN), the Melbourne Australia company specializing in neurodegenerative disorders, rose 18.10% Wednesday on 9 times average volume.
Prana Biotechnology reported Wednesday that it had been cited in an interview in The Life Sciences Report with George Zavoico, Ph.D., senior equity analyst and managing director with MLV & Co., as the only drug company to address in clinical trials the control of transition metal levels in neuronal synapses, a key event in age-related dysfunction of the brain. The Report citing Prana is titled, "Seven Innovative Biotechs That Could Soar By Year-End".
Prana Biotechnology closed at $2.48 on Wednesday.
Quaterra Resources (NYSE: QMM), the Vancouver, BC junior exploration company, rose 11.45% Wednesday on 7 times average volume.
Quaterra Resources and its 50% joint-venture partner Blackberry Ventures I, LLC, announced Wednesday that an independent preliminary economic assessment has concluded that their Nieves silver property in Zacatecas State, Mexico, has the potential to be developed as an open pit mine that would average more than five million ounces of silver production per year over a projected ten-year mine life.
Quaterra Resources closed at $0.37 on Wednesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.